| Product Name |
Anti-LAG3 Monoclonal Antibody, Recombinant |
| Catalog # |
EG-374 |
| Size |
100 µg |
| Key Features |
- Rabbit monoclonal antibody produced in HEK293 cells under serum-free, protein-free conditions
- Purified by Protein A affinity chromatography
- High batch-to-batch consistency and reproducibility
- Long-term supply security
|
| Clone Number |
M36 |
| Immunogen |
Recombinant extracellular domain of LAG3 expressed and purified from HEK293 cells |
| Target |
Extracellular region of LAG3 (CD223) |
| Species Cross-Reactivity |
Human |
| Applications |
Flow Cytometry, Immunoprecipitation (IP), ELISA |
| Recommended Working Concentrations |
- Flow Cytometry / ELISA: 5 µg/mL final concentration
- Immunoprecipitation: 10 µg per 0.3–0.5 mg cell lysate
|
| Background |
LAG3 (CD223) is an immune checkpoint receptor expressed on activated T cells. Its upregulation is critical for preventing T cell overactivation and autoimmunity. Persistent antigen stimulation leads to sustained LAG3 expression, contributing to T cell exhaustion. Neutralizing antibodies targeting LAG3, alone or combined with PD-1/PD-L1 blockade, are under clinical investigation as promising immunotherapies for solid tumors. Known LAG3 ligands include MHC class II, FGL-1, and Galectin-3. Additionally, LAG3 can be cleaved by ADAM10/17 metalloproteinases, releasing soluble forms into circulation. The M36 antibody weakly inhibits LAG3 binding to MHC II-expressing Raji cells at high concentrations.
Reference:
Lawrence P. Andrews, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276:80-96.
|
| Quality Control |
A) Flow cytometry analysis of LAG3 surface expression on activated peripheral blood mononuclear cells (PBMCs). PBMCs were stimulated in vitro with anti-CD3/anti-CD28 beads. 1 × 106 activated PBMCs were incubated with 5 µg antibody in 1 mL PBS containing 5% BSA. Binding was detected with Cy5-conjugated goat anti-rabbit secondary antibody. Shaded area: isotype control; red line: PBMCs activated for 1 day; green line: 3 days; blue line: 7 days.
B) Blocking activity of M36 antibody. Recombinant LAG3 extracellular domain (LAG3ECD-hFc) binding to Raji cells at 10 µg/mL was assessed. M36 antibody did not block binding at 1 and 5 µg/mL, and partially blocked at 20 µg/mL.
|
| Concentration |
As indicated on the vial label |
| Formulation |
80% PBS, pH 7.4; 20% glycerol; 5% trehalose; 0.04% sodium azide (preservative) |
| Shipping |
Shipped on blue ice |
| Storage |
-20 to -70 °C (long-term)
4 °C (up to one week)
For frequent use, aliquot to avoid repeated freeze-thaw cycles.
|